Clinical Trials Logo
  1. Home
  2. Dystrophic Epidermolysis Bullosa
  3. NCT02579369

Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa Clinical Trial

Official title:
A Phase 1/2 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Clinical Trial Summary

This is a phase I/II open-label study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Dystrophic Epidermolysis Bullosa.

Clinical Trial Description

ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a Dystrophic Epidermolysis Bullosa. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02579369
Study type Interventional
Source Anterogen Co., Ltd.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date December 8, 2015
Completion date April 30, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03536143 - A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients Phase 1/Phase 2
Recruiting NCT04917887 - Long-Term Follow-up Protocol
Completed NCT04917874 - A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa Phase 3
Terminated NCT03578029 - Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa Phase 2
Completed NCT03472287 - To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB) Phase 1
Recruiting NCT05157958 - Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa Phase 2
Withdrawn NCT01528306 - A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa Phase 2
Completed NCT02178969 - Short Term Observational Study in DEB Patients
Withdrawn NCT04214002 - The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)
Recruiting NCT04757727 - Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)
Withdrawn NCT01768026 - Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa N/A
Completed NCT01538862 - Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa N/A
Completed NCT03183934 - A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial
Withdrawn NCT02004600 - Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB N/A
Completed NCT04491604 - Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB Phase 3
Not yet recruiting NCT05529134 - Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene Phase 1/Phase 2
Not yet recruiting NCT04173650 - MSC EVs in Dystrophic Epidermolysis Bullosa Phase 1/Phase 2